Table 2.
Results of the Taperloc® femoral component
| Study | Year | Specific selection | Follow-up (years) | Survivorship |
|---|---|---|---|---|
| Hozack et al. [27] | 1996 | — | 6.1 | 100% |
| McLaughlin & Lee [48] | 1997 | — | 10 | 98.2% |
| Rao et al. [58] | 1998 | No adverse effects from immediate weight bearing | 2 | 100% |
| Sakalkale et al. [62] | 1999 | — | 10.2 | 90.1% |
| McLaughlin & Lee [49] | 2000 | — | 10 | 98.2% |
| Keisu et al. [30] | 2001 | Rheumatoid arthritis | 8 | 100% |
| Keisu et al. [31] | 2001 | Age 80 years or older | 5 | 100% |
| Purtill et al. [57] | 2001 | — | 11 | 99.5% |
| Parvizi et al. [56] | 2004 | — | 11 | 99.2% |
| McLaughlin & Lee [50] | 2006 | Obesity did not impair outcome | 14.5 | 94.7% |
| McLaughlin & Lee [51] | 2008 | — | 20 | 87% |